Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Navlimetostat + Nab-paclitaxel/Gemcitabine in Untreated Metastatic Pancreatic Ductal Adenocarcinoma
NCT07076121Phase 3Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2025
- Primary completion
- May 2029
- Modality
- Small Molecules
- Countries
- 36
01
Overview
A Phase 3 trial of navlimetostat in pancreatic ductal adenocarcinoma (PDAC), sponsored by Bristol Myers Squibb. Started Oct 2025; status: active, not recruiting.
02
Drugs
navlimetostat
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT07076121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07076121.